Alumis (ALMS) Corporate presentation summary

Clinical program highlights

• Envudeucitinib achieved highly statistically significant efficacy in two Phase 3 psoriasis trials, meeting all primary and secondary endpoints with deep skin clearance and rapid onset of action through Week 24.

• Safety profile was favorable and consistent with earlier studies, with most adverse events mild to moderate and transient.

• Patient populations in ONWARD1 and ONWARD2 were balanced, with comparable demographics and disease characteristics.

• Over 1,700 patients were enrolled across more than 270 sites globally in just 10 months.

• Additional long-term efficacy and safety data, as well as NDA filing, are anticipated in the second half of 2026.

Market opportunity and competitive positioning

• Psoriasis and lupus markets are projected to reach $40B and $11B globally by 2032, with high-efficacy orals expected to drive growth.

• Envudeucitinib demonstrated skin clearance rates similar to or better than key competitors, including icotrokinra and Sotyktu.

• Significant unmet need remains in psoriasis, with most patients untreated or undertreated and high discontinuation rates for current orals.

• High-efficacy oral therapies are well-positioned to capture share in a fragmented market with high switching rates and access barriers for biologics.

• Envudeucitinib’s profile—high efficacy, rapid onset, convenience, and safety—is compelling to both physicians and patients.

Pipeline and strategic outlook

• Two precision-engineered TYK2 inhibitors, envudeucitinib and A-005, offer broad potential across immune-mediated diseases, with a total addressable market exceeding $180B by 2032.

• Envudeucitinib is advancing in SLE, with a fully enrolled Phase 2b LUMUS trial and topline results expected in Q3 2026.

• A-005 is Phase 2 ready, showing full CNS penetration and potential for neuroinflammatory and peripheral immune diseases.

• Multiple near-term milestones are expected in 2026, including additional data readouts, NDA filing, and strategic reviews.

• Cash position of $632M provides runway into Q4 2027, supporting ongoing and planned development activities.